Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, Choo EJ, Curiac D, Di Paolo E, Dionne M, Eckermann T, Esen M, Ferguson M, Ghesquiere W, Hwang SJ, Avelino-Silva TJ, Kosina P, Liu CS, Markkula J, Moeckesch B, Murta de Oliveira C, Park DW, Pauksens K, Pirrotta P, Plassmann G, Pretswell C, Rombo L, Salaun B, Sanmartin Berglund J, Schenkenberger I, Schwarz T, Shi M, Ukkonen B, Zahaf T, Zerbini C, Schuind A, Cunningham AL; Zoster-049 Study Group. Boutry C, et al. Among authors: pirrotta p. Clin Infect Dis. 2022 Apr 28;74(8):1459-1467. doi: 10.1093/cid/ciab629. Clin Infect Dis. 2022. PMID: 34283213 Free PMC article. Clinical Trial.
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination.
Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, Mwakingwe-Omari A; Zoster-049 Study Group. Strezova A, et al. Among authors: pirrotta p. Open Forum Infect Dis. 2022 Oct 23;9(10):ofac485. doi: 10.1093/ofid/ofac485. eCollection 2022 Oct. Open Forum Infect Dis. 2022. PMID: 36299530 Free PMC article.
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.
Naficy A, Kuxhausen A, Pirrotta P, Leav B, Miller J, Anteyi K, Danier J, Breuer T, Mwakingwe-Omari A. Naficy A, et al. Among authors: pirrotta p. Clin Infect Dis. 2023 Nov 11;77(9):1238-1246. doi: 10.1093/cid/ciad361. Clin Infect Dis. 2023. PMID: 37335963 Free PMC article. Clinical Trial.
Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine circovirus-free) with routine childhood vaccines in infants in the United States: Results from a phase 3, randomized trial.
Abu-Elyazeed R, Klein NP, Moerman L, Povey M, Pruitt A, Senders S, Silas P, Bi D; Rota-090 Study Group. Abu-Elyazeed R, et al. Vaccine. 2021 Mar 5;39(10):1534-1543. doi: 10.1016/j.vaccine.2020.08.070. Epub 2020 Oct 17. Vaccine. 2021. PMID: 33077301 Free article. Clinical Trial.
Nanovesicular Mediation of the Gut-Brain Axis by Probiotics: Insights into Irritable Bowel Syndrome.
Santonocito R, Paladino L, Vitale AM, D'Amico G, Zummo FP, Pirrotta P, Raccosta S, Manno M, Accomando S, D'Arpa F, Carini F, Barone R, Rappa F, Marino Gammazza A, Bucchieri F, Cappello F, Caruso Bavisotto C. Santonocito R, et al. Among authors: pirrotta p. Biology (Basel). 2024 Apr 25;13(5):296. doi: 10.3390/biology13050296. Biology (Basel). 2024. PMID: 38785778 Free PMC article.
Cefotaxime in a single daily dose in lower urinary tract infections.
Peralta S, Affronti M, Malta R, Delle Vedove G, Pirrotta P, Rotondo G, Paternostro D, Rini GB, Di Rosa S. Peralta S, et al. Among authors: pirrotta p. J Chemother. 1989 Jul;1(4 Suppl):847-8. J Chemother. 1989. PMID: 16312666 No abstract available.
11 results